. 2018 Jul 31;25(11):3341–3349. doi: 10.1245/s10434-018-6660-x

Table 2.

Overall and melanoma-specific survival for patients stratified according to peripheral blood ratios

Baseline biomarker			Crude risk		Adjusted risk^a
Baseline biomarker			HR (95% CI)	p value	HR (95% CI)	p value	Resampled^b p value
Overall survival: individual biomarker
Continuous	NLR		1.1 (1.0 to 1.2)	0.07	0.8 (0.6 to 1.0)	0.03	< 0.001
	PLR		1.0 (1.0 to 1.0)	0.9	1.0 (1.0 to 1.0)	< 0.001	< 0.001
	LMR		1.0 (0.9 to 1.1)	0.6	1.0 (0.9 to 1.1)	0.8	0.6
Dichotomized	NLR	< 2.5	0.8 (0.6 to 1.1)	0.2	2.2 (2.0 to 2.3)	< 0.001	< 0.001
	NLR	≥ 2.5	1 (referent)	0.2	1 (referent)	< 0.001	< 0.001
	PLR	< 100	1.2 (0.9 to 1.8)	0.2	1.8 (1.7 to 1.8)	< 0.001	< 0.001
	PLR	≥ 100	1 (referent)	0.2	1 (referent)	< 0.001	< 0.001
	LMR	< 9	1 (referent)	0.3	1 (referent)	0.4	0.03
	LMR	≥ 9	1.5 (0.6 to 3.8)	0.3	1.3 (0.6 to 2.6)	0.4	0.03
Overall survival: compound biomarker
	NLR-low and PLR-low		1.1 (0.8 to 1.6)	0.02	3.0 (2.4 to 3.7)	< 0.001	< 0.001
	NLR-high or PLR-high		0.7 (0.5 to 0.9)		1.7 (1.1 to 2.7)
	NLR-high and PLR-high		1 (referent)		1 (referent)
Melanoma-specific survival: individual biomarker
Continuous	NLR		1.1 (0.9 to 1.2)	0.7	0.8 (0.6 to 1.0)	0.07	< 0.001
	PLR		1.0 (1.0 to 1.0)	0.6	1.0 (1.0 to 1.0)	0.05	< 0.001
	LMR		1.0 (0.9 to 1.1)	0.9	0.9 (0.9 to 1.0)	0.5	0.2
Dichotomized	NLR	< 2.5	0.9 (0.7 to 1.3)	0.8	1.9 (1.6 to 2.2)	< 0.001	< 0.001
	NLR	≥ 2.5	1 (referent)	0.8	1 (referent)	< 0.001	< 0.001
	PLR	< 100	1.4 (0.9 to 2.0)	0.1	1.9 (1.7 to 2.2)	< 0.001	< 0.001
	PLR	≥ 100	1 (referent)	0.1	1 (referent)	< 0.001	< 0.001
	LMR	< 9	1 (referent)	0.8	1 (referent)	0.9	0.9
	LMR	≥ 9	1.2 (0.4 to 3.8)	0.8	0.9 (0.2 to 4.8)	0.9	0.9
Melanoma-specific survival: compound biomarker
	NLR-low and PLR-low		1.3 (0.9 to 2.0)	0.045	3.0 (2.0 to 4.2)	< 0.001	< 0.001
	NLR-high or PLR-high		0.8 (0.5 to 1.1)		1.4 (0.8 to 2.5)
	NLR-high and PLR-high		1 (referent)		1 (referent)

HR hazard ratio; CI confidence interval; NLR neutrophil–lymphocyte ratio; PLR platelet–lymphocyte ratio; LMR lymphocyte-monocyte ratio

^aEach biomarker was examined individually by Cox regression, with adjustment, for age, Breslow thickness (mm), and mitotic rate (per mm²) as continuous variables; and for sex, ulceration, vascular invasion, tumor-infiltrating lymphocytes (TILs), regression, microsatellites, and sentinel lymph node involvement as categorical variables. CIs are adjusted for clustering

^bLossless non-parametric bootstrapping by resampling with replacement, with 1000 iterations. Low NLR was defined as < 2.5, whereas high NLR was defined as ≥ 2.5. Low PLR was defined as < 100, whereas high PLR was defined as ≥ 100